Virtual Library

Start Your Search

M. Tandhansakul

Author of

  • +

    Poster Display session (Friday) (ID 65)

    • Event: ELCC 2018
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
    • +

      161P - The survival of advanced non-small cell lung cancer with epidermal growth factor receptor in Thailand: A single instituition review (ID 183)

      12:30 - 13:00  |  Author(s): M. Tandhansakul

      • Abstract
      • Slides

      EGFR TKIs can improve progression free survival in treatment naive EGFR mutant NSCLC compared with platinum based chemotherapy, but no statistical significant difference in overall survival. The median survival time of EGFR mutant NSCLC treated at least 2 systemic chemotherapy regimens and one EGFR TKIs was 34.8 months in previous study.

      We retrospectively reviewed the medical record of advanced NSCLC cases treated with EGFR TKIs in Chulabhorn Hospital during 2009–2012. The primary objective was to determine the median survival time of advanced NSCLC patients who received EGFR-TKIs in Chulabhorn Hospital. The secondary objective was to identify the difference of survival between EGFR mutation status groups. The overall survival was analyzed by Kaplan Meier curve. The overall survival in EGFR mutation status was compared by Log rank test.

      There were 73 patients with median follow up time of 17.09 months. EGFR TKIs were given as first, second, and third line treatment in 18 (24.7%), 29 (39.7%), and 22 (30.1%) patients, respectively. EGFR mutation status was positive, negative and unknown in 14 (19.17%), 15 (20.8%), and 43 (59.7%) patients. Exon 19 deletion mutation was presented in 8 (57.1%) patients while there was 5 (35.7%) patients with exon 21 L858R substitution. There was one patient with exon 19 G729E substituition. The median overall survival time was 30.01 months (95%CI: 18.71, 49.48 months) in all patients, 49.49 months (95%CI: 15.93, NR) in EGFR mutant (N= 14), 20.96 months (95%CI: 10.64, NR) in EGFR wild type (N= 15), and 27.74 months (95%CI: 18.71, NR) in unknown EGFR mutation status (N = 43). No statistical significant difference of overall survival was noted between EGFR mutation status (p values = 0.51).

      EGFR mutationNmedian OS(months)95%CI

      The median survival time for Thai patients treated with EGFR TKIs was comparable with historical data irrespective to EGFR mutation status. In EGFR mutant cases, the median survival time was nearly 4 years. EGFR TKIs in any lines of treatment can prolong the survival of NSCLC patients.

      Clinical trial identification:

      Legal entity responsible for the study:
      Chulabhorn Hospital

      Has not received any funding

      All authors have declared no conflicts of interest.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.